Clinical trials: Alzheimer Disease, Early Onset, open to volunteers
Alzheimer Disease, Early Onset
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a…
- Trial name
- FUS-AD (NCT06600880)
- Testing
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Alzheimer Disease, Early Onset, Posterior Cortical Atrophy
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
Patients with Alzheimer's disease and with early onset of symptoms (<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground.
- Trial name
- PET-AL (NCT04150198)
- Testing
- TEP/IRM
- Where
- 2 sites in France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Early-Onset Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with…
- Trial name
- NCT05231785
- Testing
- ALN-APP
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimers Disease, Dementia
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU-002 (NCT06647498)
- Testing
- Remternetug
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Down Syndrome, Cognitive Decline
GnRH Therapy on Cognition in Down Syndrome
Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old.
- Conditions
- Down Syndrome, Cognitive Decline, Alzheimer Disease, Early Onset, Olfaction Disorders
- Trial name
- NCT04390646
- Testing
- GnRH, gonadorelin acetate, 0.9% NaCl
- Where
- Switzerland
- Volunteers
- 56 people
- Sponsor
- Nelly Pitteloud
Alzheimer Disease, Early Onset
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants…
- Trial name
- NCT07328451
- Testing
- DNL628
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Denali Therapeutics Inc.
Alzheimer Disease, Alzheimer Disease, Early Onset
Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies.
- Trial name
- TMSLA (NCT07036328)
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- Willem de Haan
Alzheimer Disease, Early Onset
Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
The purpose of this study is to generate preliminary data on the benefit of computerized cognitive training and Tai Chi- Qi Gong training in participants with Early-Onset Alzheimer's Disease.
- Trial name
- LITES (NCT05573490)
- Testing
- Cognitive Training, Tai Chi- Qi Gong, Brain Games
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Indiana University
Alzheimer Disease
Lecanemab for Early Onset Familial Alzheimer's Disease
The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD.
- Trial name
- NCT06883019
- Where
- 15 sites in China
- Volunteers
- 114 people
- Sponsor
- RenJi Hospital
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Mild Cognitive Impairment (MCI), Dementia
A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia
The goal of this clinical trial is to learn if an integrated protocol using multifocal non invasive brain stimulation and brain recording combined with cognitive training is effective in treating cognitive and affective…
- Conditions
- Mild Cognitive Impairment (MCI), Dementia, Alzheimer Disease, Early Onset, Alzheimer Disease
- Trial name
- MuSt-MID (NCT06668610)
- Testing
- StarStim 32, Neuroelectrics, Spain - Real multifocal tDCS, Cognitive treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Campania Luigi Vanvitelli
Alzheimers Disease, Dementia
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation.
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT05552157)
- Testing
- Remternetug (SC)
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Early Onset, Parkinson Disease
Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity
The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal…
- Trial name
- NODAL (NCT06080659)
- Testing
- fMRI, CONFMEM
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA)
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
- Conditions
- Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease
- Trial name
- NCT02740634
- Testing
- F-18 AV 1451, C-11 PiB
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Alzheimer Disease, Alzheimer Disease, Early Onset
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG.
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes)
- Trial name
- NCT05655195
- Testing
- GENUS device (Active Settings)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts Institute of Technology
Alzheimer Disease, Early Onset
MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease
Patients with Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) may or may not develop Alzheimer's disease (AD) dementia.
- Trial name
- MIMA-P (NCT06099587)
- Testing
- high-resolution diffusion MRI
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Rennes University Hospital
Alzheimer Disease, Alzheimer Disease, Early Onset
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild…
- Trial name
- NCT07221344
- Testing
- ARO-MAPT-SC
- Where
- 4 sites in Canada, New Zealand
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Dementia, Early Onset, Alzheimer Dementia (AD)
Genetic Studies of Early-onset Dementia
The aim of this study is to identify genetic factors that contribute to risk and progression of early-onset dementia (loss of memory function before the age of 70 years) across all ethnic groups, including Alzheimer's Disease…
- Conditions
- Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
- Trial name
- NCT04906863
- Testing
- Blood draw, Neurocognitive testing, Medical questionnaire
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Alzheimer Disease (AD)
Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease
This is an open-label, single-center, phase I clinical study in patients with moderate-to-severe early-onset Alzheimer's disease.
- Trial name
- NCT07554872
- Testing
- Neural Stem Cell-Derived Exosomes
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Mental Health Center